MX2024006933A - Formas en estado solido de un inhibidor de fgfr. - Google Patents

Formas en estado solido de un inhibidor de fgfr.

Info

Publication number
MX2024006933A
MX2024006933A MX2024006933A MX2024006933A MX2024006933A MX 2024006933 A MX2024006933 A MX 2024006933A MX 2024006933 A MX2024006933 A MX 2024006933A MX 2024006933 A MX2024006933 A MX 2024006933A MX 2024006933 A MX2024006933 A MX 2024006933A
Authority
MX
Mexico
Prior art keywords
solid state
state forms
fgfr inhibitor
forms
yclopropyl
Prior art date
Application number
MX2024006933A
Other languages
English (en)
Spanish (es)
Inventor
Stephen W Kaldor
Toufike Kanouni
Jayachandra P Reddy
John Tyhonas
Robert Kania
Jason M Cox
Andrew Phimister
Shubham Chopade
Preetanshu Pandey
Original Assignee
Kinnate Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinnate Biopharma Inc filed Critical Kinnate Biopharma Inc
Publication of MX2024006933A publication Critical patent/MX2024006933A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
MX2024006933A 2021-12-08 2022-12-07 Formas en estado solido de un inhibidor de fgfr. MX2024006933A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163287212P 2021-12-08 2021-12-08
PCT/US2022/081060 WO2023107980A1 (en) 2021-12-08 2022-12-07 Solid state forms of an fgfr inhibitor

Publications (1)

Publication Number Publication Date
MX2024006933A true MX2024006933A (es) 2024-08-26

Family

ID=86731361

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006933A MX2024006933A (es) 2021-12-08 2022-12-07 Formas en estado solido de un inhibidor de fgfr.

Country Status (12)

Country Link
US (1) US20250059170A1 (enExample)
EP (1) EP4444302A4 (enExample)
JP (1) JP2024542840A (enExample)
KR (1) KR20240119095A (enExample)
CN (1) CN118804748A (enExample)
AU (1) AU2022407440A1 (enExample)
CA (1) CA3239792A1 (enExample)
CL (1) CL2024001679A1 (enExample)
IL (1) IL313359A (enExample)
MX (1) MX2024006933A (enExample)
TW (1) TW202332432A (enExample)
WO (1) WO2023107980A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023529867A (ja) 2020-06-05 2023-07-12 キネート バイオファーマ インク． 線維芽細胞増殖因子受容体キナーゼの阻害剤
KR20240115884A (ko) * 2021-12-08 2024-07-26 킨네이트 바이오파마 인크. Fgfr 키나제 억제제를 이용하는 암의 치료

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015008844A1 (ja) * 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
CN107840842A (zh) * 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
WO2020236524A1 (en) * 2019-05-17 2020-11-26 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
JP2023529867A (ja) * 2020-06-05 2023-07-12 キネート バイオファーマ インク． 線維芽細胞増殖因子受容体キナーゼの阻害剤

Also Published As

Publication number Publication date
WO2023107980A1 (en) 2023-06-15
US20250059170A1 (en) 2025-02-20
KR20240119095A (ko) 2024-08-06
CN118804748A (zh) 2024-10-18
EP4444302A1 (en) 2024-10-16
EP4444302A4 (en) 2025-09-03
AU2022407440A1 (en) 2024-06-20
CL2024001679A1 (es) 2024-11-29
TW202332432A (zh) 2023-08-16
IL313359A (en) 2024-08-01
CA3239792A1 (en) 2023-06-15
JP2024542840A (ja) 2024-11-15

Similar Documents

Publication Publication Date Title
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
MX2009009591A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
BRPI0615307A2 (pt) agonistas de adrenorreceptor alfa2c
NO20091326L (no) Indazolderivater som modulatorer av interleukin-1-reseptor-assosiert kinase
PH12016502242A1 (en) 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
WO2008076862A3 (en) 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors
NO20084435L (no) C-MET proteinkinaseinhibitorer
CL2008002129A1 (es) Compuestos derivados de (1h-indazol-3-il)-amidas sustituidas, inhibidores de quinasa; composicion farmaceutica; procedimiento de preparacion; y uso del compuesto para el tratamiento del cancer.
CL2007000601A1 (es) Compuestos derivados de heterobiciclos pirazolicos, inhibidores de la actividad de proteina tiroxina quinasa; composicion farmaceutica que comprende dichos compuestos; y uso de los compuestos en el tratamiento de una enfermedad hiperproliferativa.
GEP20135724B (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes
CL2024001679A1 (es) Formas en estado sólido de un inhibidor de fgfr
WO2006029153A3 (en) Monocyclic anilide spirolactam cgrp receptor antagonists
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
WO2008002571A3 (en) Human protein tyrosine phosphatase inhibitors and methods of use
MX2009012000A (es) Derivados de pirazol heteroarilo sustituidos utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis.
WO2008033562A3 (en) Kinase inhibitor compounds
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
MY154869A (en) Composition for treating metabolic syndrome
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
TNSN08432A1 (en) Pieridinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2007117692A3 (en) Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
WO2008112159A3 (en) Monocyclic anilide spirolactam cgrp receptor antagonists